• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cost-Effectiveness Threshold for Healthcare: Justification and Quantification.医疗保健成本效益阈值:理由与量化。
Inquiry. 2022 Jan-Dec;59:469580221081438. doi: 10.1177/00469580221081438.
2
Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.确定实现全民健康覆盖的效率路径:基于预期寿命和卫生支出增长的 174 个国家的成本效益阈值。
Lancet Glob Health. 2023 Jun;11(6):e833-e842. doi: 10.1016/S2214-109X(23)00162-6.
3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds.系统评价医疗支出对健康结果测量的影响:对成本效益阈值的启示。
Expert Rev Pharmacoecon Outcomes Res. 2024 Feb;24(2):203-215. doi: 10.1080/14737167.2023.2296562. Epub 2024 Jan 25.
4
Framework for developing cost-effectiveness analysis threshold: the case of Egypt.制定成本效益分析阈值的框架:以埃及为例。
J Egypt Public Health Assoc. 2024 Jun 3;99(1):12. doi: 10.1186/s42506-024-00159-7.
5
Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life.基于统计生命价值的中国质量调整生命年成本效益阈值的估算。
Eur J Health Econ. 2022 Jun;23(4):607-615. doi: 10.1007/s10198-021-01384-z. Epub 2021 Oct 16.
6
A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?对获取每质量调整生命年支付意愿的研究进行的系统评价:这是否能证明成本效益阈值的合理性?
PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015.
7
On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review.医疗成本效益阈值是基于什么设定的?相互冲突的观点和数据缺失:一项系统综述。
Glob Health Action. 2018;11(1):1447828. doi: 10.1080/16549716.2018.1447828.
8
ANALYSIS OF TRENDS IN LIFE EXPECTANCIES AND PER CAPITA GROSS DOMESTIC PRODUCT AS WELL AS PHARMACEUTICAL AND NON-PHARMACEUTICAL HEALTHCARE EXPENDITURES.人均预期寿命、人均国内生产总值以及医药和非医药医疗保健支出的趋势分析
Acta Pol Pharm. 2015 Sep-Oct;72(5):1045-50.
9
Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.基于支付意愿和人均 GDP 估算医疗保健增量成本效益阈值范围:系统评价。
PLoS One. 2022 Apr 14;17(4):e0266934. doi: 10.1371/journal.pone.0266934. eCollection 2022.
10
Cost effectiveness of cancer treatment in Taiwan.台湾癌症治疗的成本效益
J Formos Med Assoc. 2016 Aug;115(8):609-18. doi: 10.1016/j.jfma.2016.04.002. Epub 2016 Jun 11.

引用本文的文献

1
Health economic value of postacute oral nutritional supplementation in older adult medical patients at risk for malnutrition: a US-based modelling approach.老年成年住院患者营养不良风险患者的急性后期口服营养补充的健康经济价值:基于美国的建模方法。
BMJ Open. 2024 Nov 17;14(11):e086787. doi: 10.1136/bmjopen-2024-086787.
2
State and National Estimates of the Cost of Emergency Department Pediatric Readiness and Lives Saved.州和国家对急诊儿科准备情况和拯救生命的成本的估计。
JAMA Netw Open. 2024 Nov 4;7(11):e2442154. doi: 10.1001/jamanetworkopen.2024.42154.
3
Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.医疗保健公共政策中使用成本效益阈值:进展与挑战。
Appl Health Econ Health Policy. 2024 Nov;22(6):797-804. doi: 10.1007/s40258-024-00900-5. Epub 2024 Jul 12.
4
Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.在中国建立成本效益阈值:一项关于健康生活年支付意愿的社区调查。
BMJ Glob Health. 2024 Jan 9;9(1):e013070. doi: 10.1136/bmjgh-2023-013070.
5
Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV-2 in the endemic phase?在流行阶段,自然和混合免疫是否使 SARS-CoV-2 疫苗频繁加强针成为多余?
Eur J Clin Invest. 2023 Feb;53(2):e13906. doi: 10.1111/eci.13906. Epub 2022 Nov 24.
6
Are Lockdowns Effective in Managing Pandemics? lockdowns 在管理大流行病方面是否有效?
Int J Environ Res Public Health. 2022 Jul 29;19(15):9295. doi: 10.3390/ijerph19159295.

本文引用的文献

1
Premature Years of Life Lost Due to Cancer in the United States in 2017.2017 年美国因癌症而损失的早年生命。
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2591-2598. doi: 10.1158/1055-9965.EPI-20-0782. Epub 2020 Nov 13.
2
Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review.成本效益分析中成本效益阈值的选择是否会对技术的最终价值产生内在影响?系统评价。
Appl Health Econ Health Policy. 2021 Mar;19(2):155-162. doi: 10.1007/s40258-020-00606-4.
3
The Moral Determinants of Health.健康的道德决定因素。
JAMA. 2020 Jul 21;324(3):225-226. doi: 10.1001/jama.2020.11129.
4
Discounting in Economic Evaluations.经济性评价中的折扣
Pharmacoeconomics. 2018 Jul;36(7):745-758. doi: 10.1007/s40273-018-0672-z.
5
On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review.医疗成本效益阈值是基于什么设定的?相互冲突的观点和数据缺失:一项系统综述。
Glob Health Action. 2018;11(1):1447828. doi: 10.1080/16549716.2018.1447828.
6
Cost-effectiveness of national health insurance programs in high-income countries: A systematic review.高收入国家国民健康保险计划的成本效益:一项系统评价。
PLoS One. 2017 Dec 15;12(12):e0189173. doi: 10.1371/journal.pone.0189173. eCollection 2017.
7
Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries.为实现卫生可持续发展目标而构建变革性卫生系统的筹资:67 个低收入和中等收入国家预计资源需求模型。
Lancet Glob Health. 2017 Sep;5(9):e875-e887. doi: 10.1016/S2214-109X(17)30263-2. Epub 2017 Jul 17.
8
Cost-Effectiveness Analysis 2.0.成本效益分析2.0
N Engl J Med. 2017 Jan 19;376(3):203-205. doi: 10.1056/NEJMp1612619.
9
Cost-effectiveness thresholds: pros and cons.成本效益阈值:利弊
Bull World Health Organ. 2016 Dec 1;94(12):925-930. doi: 10.2471/BLT.15.164418. Epub 2016 Sep 19.
10
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.国家层面的成本效益阈值:初步估计及进一步研究的必要性。
Value Health. 2016 Dec;19(8):929-935. doi: 10.1016/j.jval.2016.02.017.

医疗保健成本效益阈值:理由与量化。

Cost-Effectiveness Threshold for Healthcare: Justification and Quantification.

机构信息

Department of Industrial Engineering, 42730Jerusalem College of Technology, Jerusalem, Israel.

Disaster Research Center, IL, 42732Ariel University, Ariel, Israel.

出版信息

Inquiry. 2022 Jan-Dec;59:469580221081438. doi: 10.1177/00469580221081438.

DOI:10.1177/00469580221081438
PMID:35549935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9109272/
Abstract

Every public health expenditure, including the one that saves lives or extends life expectancy of particular persons (target population), bears a cost. Although cost-effectiveness analysis (CEA) is routinely performed in health policy, ethical justification of CEA is rarely discussed. Also, there is neither consensus value nor even consensus method for determining cost-effectiveness threshold (CET) for life-extending measures. In this study, we performed ethical analysis of CEA by policy impact assessment based on connection of health and wealth (poorer people have statistically shorter life expectancies) and concluded that CEA is not only a practical but also an ethical necessity. To quantify CET, we used three independent methods: (1) literature survey of analyzing salaries in risky occupations, (2) utilizing Prospect Theory suggesting that people value their lives in monetary terms twice more than their lifetime earnings, and (3) literature survey of the U.S. current legal practice. To the best of our knowledge, nobody applied method (2) to determine CET. The three methods yielded rather similar results with CET about 1.0 ± 0.4 gross domestic product per capita (GDPpc) per quality-adjusted life-year. Therefore, a sum of not higher than 140% GDPpc is statistically sufficient to "purchase" an additional year of life-or, alternatively, to "rob" one year of life if taken away. Therefore, 140% GDP per capita per quality-adjusted life-year should be considered as the upper limit of prudent and ethically justified expenditure on life extension programs.

摘要

每一项公共卫生支出,包括那些拯救特定人群(目标人群)生命或延长其预期寿命的支出,都需要承担成本。尽管成本效益分析(CEA)在卫生政策中经常进行,但很少讨论 CEA 的伦理合理性。此外,对于延长寿命的措施,既没有确定成本效益阈值(CET)的共识价值,也没有共识方法。在这项研究中,我们通过基于健康与财富的联系(较贫穷的人预期寿命统计上较短)的政策影响评估对 CEA 进行了伦理分析,并得出结论,CEA 不仅是一种实际需要,也是一种伦理必要。为了量化 CET,我们使用了三种独立的方法:(1)分析高风险职业薪酬的文献调查,(2)利用前景理论表明,人们将自己的生命在货币价值上的重视程度比他们的一生收入高出两倍,以及(3)对美国当前法律实践的文献调查。据我们所知,没有人使用方法(2)来确定 CET。这三种方法得出的 CET 结果非常相似,约为 1.0 ± 0.4 人均国内生产总值(GDPpc)每质量调整生命年。因此,不高于 140%的 GDPpc 的总和在统计学上足以“购买”额外的一年生命,或者,如果被剥夺,就相当于“抢夺”一年生命。因此,每质量调整生命年 140%的人均 GDP 应被视为审慎和合理地用于延长生命计划支出的上限。